Section 7

Synthetic Cathinones and their analogues.

Any substance, (other than a substance listed in the above

Section 2 or bupropion) that is structurally derived from 2- amino-1-phenylpropan-1-one by modification in any of the atom by any substitution by an atom or a specific group of atoms (functional group) or substituent including any salt or stereoisomeric form thereof, and any preparation or product containing thereof.

8. Aminodanes and their analogues.

Any aminodane (other than listed in the above Sections) and any substance, including any salt or stereoisomeric form of such substances, and any preparation or product containing such substances.

9. Phenethylamines and their analogues.

Any phenethylamine substance (other than a substance listed in the above Section 2), including any type of positional isomer in the phenyl ring by modification in any of the atom by any substitution by an atom or a specific group of atoms (functional group), substituted substances such as the ‘2C series’, ring substituted amphetamines such as the ‘D series’, any benzodifurans or its substituent and any others substance thereof, including any salt or stereoisomeric form thereof, and any preparation or product containing thereof.

10. Any substance (not being bupropion, cathinone, diethylpropion, pyrovalerone or not being listed for the time being specified in above Sections) structurally derived from 2–amino–1–phenyl–

1– propanone by modification in any of the following ways, that is to say-

by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

by substitution at the 3–position with an alkyl substituent;

by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.

by substitution in the ring system to any extent with alkyl, alkoxy, alkylenedioxy haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

by substitution at the 3–position with an alkyl substituent;

by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups;

by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group;

by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.

Any substance other than listed in above Section 2, containing a 3-(1-naphthylmethyl)indole structure with substitution at the nitrogen atom of the indole ring by an atom or any specific group of atoms (functional group), and any derivatives of the above substances including any salt or stereoisomeric form of the above substances or derivatives, and any preparation or product containing the above substances or derivatives;

Any substance other than listed in above Section 2, containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an atom or any specific group of atoms (functional group), and any derivatives of the above substances containing functional groups, including any salt or stereoisomeric form of the above substances or derivatives, and any preparation or product containing the above substances or derivative;

Any substance other than listed in above Section 2, containing a naphthylideneindene structure with any substitution at any position of the indene ring by an atom or any specific group of atoms (functional group), and any derivatives of the above substances containing hydroxy and/or carboxylic acid groups, including any salt or stereoisomeric form of the above substances or derivatives, and any preparation or product containing the above substances or derivatives;

Any substance other than listed in above Section 2, containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at any position of the phenolic ring by an atom or any specific group of atoms (functional group), and any derivatives of the above substances containing hydroxy and/or carboxylic acid groups, including any salt or stereoisomeric form of the above substances or derivatives, and any preparation or product containing the above substances or derivatives.

the esters, ethers, and amides of GHB; and

all substances from which GHB can be derived, including

1,4-butanediol;

gamma-aminobutyric acid;

gamma-butyrolactone;

gamma-hydroxybutyraldehyde; and

the salts of GHB (including sodium oxybate) and the salts of any substance referred to in paragraph (a) or paragraph (b); and

any substance, preparation, or mixture containing any proportion of GHB or any substance referred to in any of paragraphs (a) to (c).

Khat (Catha edulis);

Kratom (Mitragyna speciosa);

Salvia (Salvia divinorum);

Chacruna (Psychiotria viridis);

Mimosa hostilis (Mimosa tenuiflora);

Hawaiian Baby Woodrose (Argyreia nervosa);

Iboga (Tabernanthe iboga), or any other plant containing any dangerous drug or a substance substantially similar to dangerous drugs or an substituted analogue of a dangerous drug listed in above

by the repeal of Part III of that Schedule and the substitution therefor of the following Part:-